Despite advancements in TB treatment, significant barriers remain that hinder effective access to essential medicines. These barriers include issues related to availability, acceptability, rational use, affordability, timely access, and geographic accessibility. Healthcare professionals, policymakers, and stakeholders need a comprehensive understanding of these dimensions to develop and implement strategies that ensure equitable access to TB care and support.
Educational aims
The aim of the webinar is to provide participants with an in-depth understanding of the various dimensions of access to medicine in the context of TB treatment, by exploring the factors of availability, acceptability, rational use, affordability, timely access, and geographic accessibility.
Topics
- Overview of access to medicine
- Dimensions of access: Availability, acceptability, rational use, affordability, timely and geographic accessibility
- Access to optimise TB treatment
Target audience
- Healthcare professionals
- Decision makers
- Policy makers
- Researchers
- TB community
Learning outcomes
- Raise awareness on the multifaceted nature of access to TB care and support.
- Highlight the importance of each dimension in optimizing TB treatment.
- Discuss current barriers and potential solutions to improving access.
- Provide practical knowledge and strategies to enhance the availability and effectiveness of TB treatment programs.
- Foster a collaborative approach among healthcare providers, policymakers, and other stakeholders to address and overcome the challenges in accessing TB care and support.
Format
This webinar will include 45 minutes of presentation, followed by interactive panel discussion and Q&A from participants.
CME credit
An application for accreditation of this webinar has been made to the European Board for Accreditation in Pneumology (EBAP) for 1 CME credit per 1-hour attendance. If accredited, the CME credit will be granted upon attendance of at least 60 minutes during the live webinar only.
What is a webinar?
A webinar closely simulates a lecture-based teaching experience. The speaker can interact with the audience, just as in a classroom setting. During the webinar, you will be asked to share your opinion on issues related to the topic using interactive polls.
All participants will be able to hear the lecturer and see the slides throughout the presentation. As a participant you will be able to pose questions or discuss ideas with the other participants via the text chat facility and the speaker will respond to the questions via the microphone.
Login guidelines
More information will be communicated in due course.
- Please log in to the webinar 20 minutes before it is scheduled to commence. If you have any technical difficulties whilst trying to log in or during the session please contact e-learning@ersnet.org.
- Check Central European Time.
- To achieve the best quality, we recommend to avoid downloading anything from the internet during your connection to the lecture and stopping all other programmes.
- Please also ensure that your audio settings are not set to mute and adjust the volume to a comfortable level.


About UNITE4TB
UNITE4TB is a public-private partnership with representation from academic institutions, small- and medium-sized enterprises (SMEs), public organisations, and pharmaceutical companies. The 7-year, €185 million project aims to accelerate and improve the clinical evaluation of combinations of existing and novel drugs, with the goal of developing new and highly active Tuberculosis (TB) treatment regimens for drug-resistant and -sensitive TB. For more information, visit the consortium website: www.unite4TB.org
Funding
The UNITE4TB project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 101007873. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA, Deutsches Zentrum für Infektionsforschung e. V. (DZIF), and Ludwig-Maximilians-Universität München (LMU). EFPIA/AP contribute to 50% of funding, whereas the contribution of DZIF and the LMU University Hospital Munich has been granted by the German Federal Ministry of Education and Research. For further information: www.imi.europa.eu
Disclaimer
This communication reflects the author’s view. Neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.
Diseases/methods:
- Respiratory Infections
- Respiratory Critical Care
Target audience
- Healthcare Professionals
- Decision Makers
- Policy Makers
- Researchers
- TB Community